Gottlieb IJ, et al. - Researchers undertook this randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of an intravenous (IV) nanocrystal formulation of meloxicam in subjects with moderate-to-severe pain following a standardized unilateral bunionectomy. In subjects with moderate-to-severe post-bunionectomy pain, meloxicam IV was generally safe and well tolerated. They noted that once-daily administration of meloxicam IV 30 mg and 60 mg conferred rapid onset of analgesia (as early as 15 minutes) with maintenance of analgesic effect for two consecutive 24-hour periods.